Cargando…

Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study

AIMS: Rapid-cycling bipolar disorder is difficult to treat and associated with greater morbidity than non-rapid-cycling disease. This post hoc analysis evaluated 28 patients with rapid-cycling bipolar I disorder from a 100-week, double-blind, placebo-controlled study assessing long-term efficacy, sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muzina, D J, Momah, C, Eudicone, J M, Pikalov, A, McQuade, R D, Marcus, R N, Sanchez, R, Carlson, B X
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2008
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2324208/ https://www.ncbi.nlm.nih.gov/pubmed/18373615 http://dx.doi.org/10.1111/j.1742-1241.2008.01735.x

Ejemplares similares

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy
por: Nelson, J. Craig, et al.
Publicado: (2014)

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
por: Muzina, David J
Publicado: (2009)

Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents
por: Sallee, Floyd, et al.
Publicado: (2017)

Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania
por: Ostacher, Michael J, et al.
Publicado: (2015)

Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2010)

Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression
por: Kato, Tadafumi, et al.
Publicado: (2020)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
por: Raghuthaman, G., et al.
Publicado: (2015)

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2009)

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2010)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

The global effect of aripiprazole monotherapy in the spectrum of symptoms in bipolar disorder: a meta-analysis
por: Fountoulakis, Konstantinos N
Publicado: (2010)

Metabolic effects of adding Topiramate on Aripiprazole in bipolar patients aged between 6-18 years, a randomized, double-blind, placebo-controlled trial
por: Arman, Soroor, et al.
Publicado: (2022)

Aripiprazole monotherapy in an adolescent worsens psychosis
por: Panigrahi, Mahima, et al.
Publicado: (2013)

The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: Nelson, J Craig, et al.
Publicado: (2008)

Comparison of Aripiprazole and Risperidone effectiveness in treating obsessive‐compulsive disorder in patients with bipolar disorder: Double‐blind, randomized clinical trial
por: Khorshidian, Faezeh, et al.
Publicado: (2023)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
por: Calisti, F., et al.
Publicado: (2021)

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
por: Kane, John M., et al.
Publicado: (2015)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman, Robert M, et al.
Publicado: (2011)

Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
por: Ichikawa, Hironobu, et al.
Publicado: (2016)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013)

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study
por: Earley, Willie R., et al.
Publicado: (2019)

Aripiprazole in the acute and maintenance phase of bipolar I disorder
por: Zupancic, Melanie, et al.
Publicado: (2012)

When to start aripiprazole therapy in patients with bipolar mania
por: Sayyaparaju, Kiran Kumar, et al.
Publicado: (2014)

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
por: Kirino, Eiji
Publicado: (2014)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial
por: Kountouras, Jannis, et al.
Publicado: (2020)

Case report: rTMS in combination with aripiprazole and sodium valproate for the maintenance treatment of rapid cycling bipolar disorder
por: Tao, Siyi, et al.
Publicado: (2023)

Neural correlates of delusional infestation responding to aripiprazole monotherapy: a case report
por: Ponson, Laura, et al.
Publicado: (2015)

Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability
por: Fagiolini, Andrea
Publicado: (2010)

The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review
por: Muneer, Ather
Publicado: (2016)

Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania
por: Rezayat, Amir Akhavan, et al.
Publicado: (2014)

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials
por: Adler, Lenard A., et al.
Publicado: (2022)

Effect of scheduled antimicrobial and nicotinamide treatment on linear growth in children in rural Tanzania: A factorial randomized, double-blind, placebo-controlled trial
por: DeBoer, Mark D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_370209r45jppe684a266hej87k